Changes in tissue prostatic acidic phosphatase during endocrine treatment of patients with prostatic carcinoma

Scandinavian Journal of Urology and Nephrology

Volumn 39, Issue 5, 2005, Pages 393-398

  Grande, Mirtha ^a   Carlström, Kjell ^a   Lundh Rozell, Barbro ^a   Stege, Reinhard ^a   Pousette, Åke ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Prostate; Prostate specific antigen; Prostatic acidic phosphatase; Prostatic cancer

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; GONADORELIN; GOSERELIN; POLYESTRADIOL PHOSPHATE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CARCINOMA; QUANTITATIVE ANALYSIS; SURVIVAL RATE; TISSUE SECTION;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CARCINOMA; ESTROGENS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE-PHOSPHATASE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 27944470097     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590500193304     Document Type: Article

References (14)

1. Huggins C, Hodges V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7.
2. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Prostate antigen - a new potential marker for prostatic cancer. Prostate 1979;2:89-96.
3. Simon HB, Nygaard KK. Clinical interpretation of total serum and "prostatic" acid phosphatase level. JAMA 1959; 171:125-9.
4. Bunting PS. Is there still a role for prostatic acid phosphatase? CSCC position statement. Clin Biochem 1999;32:591-4.
5. Hasenson M, Lundh B, Stege R, Carlström K, Pousette Å. PAP and PSA in prostatic carcinoma cell lines and aspiration biopsies: relation to hormone sensitivity and to cytological grading. Prostate 1989;14:83-90.
6. Stege R, Lundh B, Tribukait B, Pousette Å, Carlström K, Hasenson M. Deoxyribonucleic acid ploidy and the direct assay of prostatic acid phosphatase and prostate specific antigen in fine needle aspiration biopsies as diagnostic methods in prostatic carcinoma. J Urol 1990;144:299-302.
7. Stege R, Tribukait B, Lundh B, Carlström K, Pousette A, Hasenson M. Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma. J Urol 1992; 148:833-7.
8. Labrie F, Dupont A, Belanger A, St-Arnaud R, Giguére M, Acourciére Y, et al. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr Rev 1986;7:67-74.
9. Carlström K, Stege R, Henriksson P, Grande M, Gunnarsson PO, Pousette Å. Possible bone-preserving capacity of high dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma. Prostate 1997;31:193-7.
10. Henttu P, Liao SS, Vihko P. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA) but down regulate the prostate acid phosphatase mRNA in the LNCaP cell line. J Clin Endocrinol Metab 1992;130:766-72.
11. Henttu P, Vihko P. Steroids inversely affect the biosynthesis and secretion of human prostatic acid phosphatase and prostate-specific antigen in the LNCaP cell line. J Steroid Biochem Mol Biol 1992;41:349-60.
12. Grande M, Carlström K, Lundh Rozell B, Stege R, Pousette Å. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients. Clin Cancer Res 2000;6:1790-5.
13. Stege R, Grande M, Carlström K, Tribukait B, Pousette A. Prognostic significance of tissue prostate-specific antigen in endocrine treated prostate carcinomas. Clin Cancer Res 2000;6:160-5.
14. Frick J, Jungwirth A, Rovan E. Androgens and the prostate. In: Nieschlag E, Behre HM, editors. Testosterone. Action, deficiency, substitution, 2nd ed. Berlin, Germany: Springer; 1998. p. 259-91.